Thermo Fisher Scientific Stock price
Equities
TMO
US8835561023
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
580 USD | -0.70% | -3.23% | +9.28% |
Financials (USD)
Sales 2024 * | 43.01B | Sales 2025 * | 46.05B | Capitalization | 221B |
---|---|---|---|---|---|
Net income 2024 * | 6.37B | Net income 2025 * | 6.94B | EV / Sales 2024 * | 5.66 x |
Net Debt 2024 * | 22.27B | Net Debt 2025 * | 17.46B | EV / Sales 2025 * | 5.18 x |
P/E ratio 2024 * |
35.2
x | P/E ratio 2025 * |
31.2
x | Employees | 122,000 |
Yield 2024 * |
0.25% | Yield 2025 * |
0.28% | Free-Float | 87.09% |
Latest transcript on Thermo Fisher Scientific
1 day | -0.70% | ||
1 week | -3.23% | ||
Current month | +1.73% | ||
1 month | +5.88% | ||
3 months | +11.84% | ||
6 months | +14.24% | ||
Current year | +9.28% |
Managers | Title | Age | Since |
---|---|---|---|
Marc Casper
CEO | Chief Executive Officer | 55 | 01-10-31 |
Director of Finance/CFO | 57 | 01-05-31 | |
Ryan Snyder
CTO | Chief Tech/Sci/R&D Officer | - | 18-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Marc Casper
CEO | Chief Executive Officer | 55 | 01-10-31 |
C. Harris
BRD | Director/Board Member | 67 | 12-03-29 |
Ruby Chandy
BRD | Director/Board Member | 62 | 22-02-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
11.69% | 2 M€ | -25.75% | ||
7.43% | 18 M€ | +5.16% | - | |
5.37% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-18 | 580 | -0.70% | 1,554,424 |
24-03-15 | 584.2 | -0.13% | 1,920,147 |
24-03-14 | 584.9 | -1.42% | 1,757,994 |
24-03-13 | 593.3 | -0.66% | 1,035,189 |
24-03-12 | 597.2 | -0.36% | 1,146,315 |
Delayed Quote Nyse, March 18, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.28% | 221B | |
+8.70% | 186B | |
+16.38% | 139B | |
+16.31% | 98.65B | |
+5.70% | 67.33B | |
+21.77% | 55.83B | |
+0.85% | 49.24B | |
+5.08% | 42.81B | |
+17.19% | 41.26B | |
+11.01% | 28.05B |